To systematically review anatomical and functional outcomes of switching therapy from bevacizumab and/or ranibizumab to aflibercept in patients with persistent macular oedema secondary to retinal vein occlusions (RVO). A systematic search of aflibercept for the treatment of persistent macular oedema secondary to branch and central RVO was performed in EMBASE, PubMed and Cochrane databases prior to June 2017. The main outcome variables described were best-corrected visual acuity (BCVA) and central macular thickness (CMT). All results were analysed and pooled using random-effects models with 95% confidence intervals (CI). Eight studies met the inclusion criteria with a total of 137 eyes, incorporating both branch and central RVO. Meta-analysis demonstrated a nonsignificant change in BCVA at 6 and 12 months following switch to aflibercept (4.40 letters, 95% CI: À3.10 to 11.90, p = 0.25 and 3.10 letters, 95% CI: À1.74 to 7.94, p = 0.21, respectively). Significant improvement in mean CMT was observed after switch to aflibercept at 6 (À256.00 lm, 95% CI: À318.00 to À194.00, p < 0.001) but not 12 months (À118.00 lm, 95% CI: À261.00 to 25.00, p = 0.11). Switching from bevacizumab/ranibizumab to aflibercept may improve persistent macular oedema secondary to RVO. However, there may be a limitation in the potential of visual recovery.
Introduction
Intravitreal antivascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of common sight-threatening retinopathies, particularly age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusions (RVO) (Wecker et al. 2017) . Antivascular endothelial growth factor (Anti-VEGF) therapy has proved not only beneficial in preventing visual loss, but has demonstrated potential for long-term vision gain in conditions such as DME and RVO. However, poor response to repeated use of anti-VEGF therapy has been demonstrated in the setting of AMD and DME (Broadhead et al. 2014; Bahrami et al. 2016) , and more recently RVO (Wolfe et al. 2016 ). These poor responders may not benefit with continued treatment with anti-VEGF therapy as the potential for visual recovery is lost (Broadhead et al. 2014) . Treatment options for these poor responders include switching to a corticosteroid, combination therapy, switching to another anti-VEGF therapy and increasing dose (Brown et al. 2010; Meyer et al. 2011; Cohen et al. 2016) .
Vascular endothelial growth factor-A (VEGF-A) is a protein upregulated in the setting of hypoxia, inducing angiogenesis and vascular permeability leading to oedema (Tah et al. 2015) . Macular oedema is a major cause of vision loss among patients with RVO, with various studies demonstrating the key role of VEGF secretion in the disease process (Penn et al. 2008) . Antivascular endothelial growth factor (Anti-VEGF) drugs include the monoclonal antibody bevacizumab and the monoclonal antibody fragment ranibizumab which both bind to all isoforms of VEGF-A (Ventrice et al. 2013) . They additionally include aflibercept, a fusion protein that combines binding domains of VEGF receptors 1 and 2 and consequently binds VEGF-A, VEGF-B and placental growth factor (Ventrice et al. 2013) .
Ranibizumab has shown to have a very potent effect on macular oedema resulting from RVO (Varma et al. 2012) , and bevacizumab has also been shown to be noninferior to ranibizumab for this indication (Khan et al. 2017) . However, the number of injections required varies widely, with some patients able to maintain control of macular oedema on three monthly injections, whilst others never achieving anatomical success despite monthly intervention (Miwa et al. 2017) . Patients with RVO can show suboptimal response to suppression of VEGF, and in these patients, it is possible that other vasoactive proteins may contribute (Campochiaro et al. 2016) .
More recently, several trials have evaluated aflibercept in the treatment of central RVO (CRVO) (GALILEO and COPERNICUS) and branch RVO (BRVO) (VIBRANT) (Brown et al. 2013; Ogura et al. 2014; Clark et al. 2016) in na€ ıve eyes. Several studies have already demonstrated the efficacy of aflibercept for refractory cases in the setting of neovascular AMD and DME (Lazzeri et al. 2015; Bahrami et al. 2017; Spooner et al. 2017) . Few have assessed the efficacy for refractory cases of macular oedema in RVO (Konidaris et al. 2017) .
The aim of this review was to investigate the outcomes of switching therapy to aflibercept among patients with BRVO or CRVO and persistent oedema despite previous treatment with either bevacizumab or ranibizumab.
Materials and Methods

Search strategy
EMBASE, PubMed and Cochrane databases were examined independently by two reviewers (KS and TH). The search stratagem was grounded on the combination of medical subject headings and keywords 'retinal vein occlusion', 'treatment resistant', 'aflibercept', 'switching', 'refractory', 'anti-vascular endothelial growth factor', and 'anti-VEGF'. Studies published prior to June 2017 were included in this meta-analysis. The citations of associated articles were examined for potential additional publications.
We limited the search to clinical studies published in peer-reviewed and English language publications. In cases of published abstracts or when data were missing or unclear, authors were contacted for interpretation and additional information.
Eligibility criteria
This meta-analysis considered studies that met the following criteria: (i) patients aged over 18 years that have persistent macular oedema secondary to RVO despite previous anti-VEGF therapy; (ii) clinical studies published in peer-reviewed journals; (iii) studies that provided at least one of the main outcome variables being best-corrected visual acuity (BCVA) or central macular thickness (CMT). Studies were excluded when only an abstract was published, and we were unable to collect the unpublished data.
Data extraction and quality assessment Data were extracted independently by the review authors who then evaluated risks of bias, following the 27-point Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. The review authors then autonomously evaluated the full-text articles and removed those that were not deemed relevant.
The Cochrane Handbook was used to acquire standard deviation (SD) from range, median or p-value when present (Higgins et al. 2003) . Bestcorrected visual acuity (BCVA) was transposed to ETDRS letter score.
Data were summarized both qualitatively and quantitatively. This was enabled by extracting data of the following characteristics from the included studies: study design (retrospective or prospective); target population (sample size); patient characteristics (age and gender); and baseline clinical characteristics (BCVA, CMT and injection intervals).
In addition to the overall metaanalysis, we also performed subgroup analysis of postswitch injection intervals. If studies had missing data in regard to subgroup analysis, these were removed from the meta-analysis.
Possible bases of bias were assessed according to the Downs and Black Checklist (Downs & Black 1998) . All included studies were evaluated as fair.
Data synthesis and analysis
The quantitative data were analysed with Comprehensive Meta-Analysis Version 2.0 (Wiley, Englewood NJ, USA). The summary statistics of effect sizes were conveyed as mean differences (for continuous data) with 95% confidence intervals. Heterogeneity was assessed with the I 2 statistic (Higgins & Thompson 2002) . A random-effects model was applied to pool the data. Publication bias was assessed by Egger's linear regression and funnel plots. Subgroup analyses were performed for BRVO and CRVO.
Results
Description of studies
A total of 13 potential articles were identified by the initial search prior to June 2017. Of these, only eight studies evaluated switching therapy in the treatment of macular oedema secondary to RVO. Therefore, all available studies met the inclusion criteria for the meta-analysis (Table 1) , with two studies assessing BRVO (Wirth et al. 2016; Tagami et al. 2017) , and six assessing CRVO (Eadie et al. 2014; Lehmann-Clarke et al. 2015; Pfau et al. 2015; Cohen et al. 2016; Papakostas et al. 2016; Konidaris et al. 2017) . Sample sizes ranged from 5 to 42, with a total of 137 eyes included in the analyses. The duration of studies ranged from 5.2 to 14 months. The literature search process and reasons for exclusion are summarized in Fig. 1 .
Reported outcomes included changes in BCVA, CMT and injection intervals. Overall, one prospective study and seven retrospective studies were included, with a mean follow-up of 6 months after converting to aflibercept.
Baseline characteristics
Baseline characteristics of the included studies are shown Table 2 . The mean age ranged from 57.0 to 77.0 years old. The mean baseline BCVA letter scores ranged from 28.3 to 72.7 ETDRS letters and were similar among the studies. Mean CMT ranged from 295.00 to 633.67 lm. Mean number of anti-VEGF injections prior to switching to aflibercept ranged from 4.5 to 17.9, with a dosing interval ranging from 4.8 to 6.8 weeks. Of note, perfusion status was only documented in four of the studies, representing 74 eyes, with 17.57% (13 eyes) of those being ischaemic RVOs (LehmannClarke et al. 2015; Pfau et al. 2015; Papakostas et al. 2016; Tagami et al. 2017) . Only one study made comment in regard to anterior segment neovascularization (Konidaris et al. 2017) , in which these patients were excluded from the study. No comments were made in regard to rubeosis.
Meta-analysis
In an attempt to extrapolate all available data, seven studies were used for the analysis of 6-month outcomes and four studies were included for 12-month analyses.
Best-corrected visual acuity
Seven studies (n = 95 eyes) were included in the evaluation of change in BCVA from baseline to month 6. Overall, the pooled results demonstrated a nonsignificant gain in BCVA from baseline with a mean increase of 4.40 letters, 95% confidence interval (CI) À3.10 to 11.90 p = 0.25 (Fig. 2) . Four studies (n = 80 eyes) were included in the evaluation of BCVA between baseline and 12 months. There was no significant change in BCVA from baseline with a mean increase of 3.10 letters (95% CI: À1.74 to 7.94, p = 0.21; Fig. 3 ). There was no significant heterogeneity found among the studies assessing BCVA for 6-and 12-month follow-up (I 2 = 0%, p = 0.93 and I 2 = 0%, p = 0.45, respectively).
Subgroup analysis by postswitch treatment intervals showed those studies with mean injection intervals of <8 weeks showed a greater mean increase of 9.62 and 9.08 letters at 6 and 12 months, respectively, compared to treatment intervals of ≥8 weeks of 3.43 and 2.09 letters (at 6 and 12 months, respectively) ( Table 3 ).
Central macular thickness
Seven studies (95 eyes) were analysed in mean change of CMT between baseline and 6 months. As a whole, the pooled results showed a significant reduction in CMT from baseline with a mean reduction of 256.00 lm (95% CI: À318.00 to À194.00, p < 0.001) (Fig. 4) .
Four studies (80 eyes) were included in the evaluation of CMT change between baseline and 12 months. There was significant reduction in CMT from baseline with a mean reduction of À118.00 lm (95% CI: À261.00 to 25.00, p = 0.107; Fig. 5 ). No heterogeneity was found between studies assessing CMT for 6-month follow-up (I 2 = 0%, p < 0.01); however, there was significant heterogeneity among studies in the 12-month follow-up (I 2 = 87.94%, p = 0.02).
Subgroup analyses
Subgroup analysis by postswitch treatment intervals showed those studies with mean injection intervals of <8 weeks showed a greater mean reduction in CMT of 225.00 and 194.00 lm at 6 and 12 months, respectively, compared to studies with treatment intervals of ≥8 weeks which showed a mean reduction of 126.00 and 20.00 lm at 6 and 12 months, respectively. (Table 3 
Publication bias
There was no evidence of possible publication bias when assessed from the funnel plots and by Egger's test (p = 0.93 BCVA 6 months; p = 0.45 BCVA 12 months; and p < 0.01 central retinal thickness (CRT) 6 months). There was evidence of possible publication bias in the analyses of CMT at 12 months (I 2 = 87.94% p = 0.02 CRT), indicating that the treatment effect was overestimated due to the small population sample sizes. However, the conclusions of homogeneity in this meta-analysis should be viewed with caution due to the small sample sizes of the included studies (Egger & Smith 1995; Sterne et al. 2000) and the wide range of baseline BCVA and CMT values.
Discussion
Despite being the second most common retinal vascular disorder (Klein et al. 2000; Coscas et al. 2011; Jaulim et al. 2013) , there were only a limited number of published studies available for inclusion in this meta-analysis. The prevalence of RVO is only 5.20 per 1000 persons, with BRVO alone accounting for 4.42 per 1000 and CRVO only 0.80 per 1000 persons (Rogers et al. 2010 ). There are limited data on how to treat eyes with persistent macular oedema and a suboptimal response to anti-VEGF therapy. If anti-VEGF therapy becomes less efficacious, there are no randomized controlled trials that provide evidence that switching to another anti-VEGF may be effective. However, given our experience in switching anti-VEGF therapies in nAMD and DME (Chang et al. 2015; Bahrami et al. 2017) , the potential benefit of switching therapy in RVO needed to be addressed. This is the first study to our knowledge providing a meta-analysis assessing switching to aflibercept to treat macular oedema secondary to RVO for patients previously treated with other anti-VEGF therapies. The meta-analysis was performed using a robust search strategy and data extraction using a systematic review process. Although the included studies had relatively small sample sizes, there was a low risk of bias and all eight studies had similar baseline characteristics.
The efficacy of aflibercept has been well established in the VIBRANT trial for BRVO, and the GALILEO and COPERNICUS trials for CRVO (Heier et al. 2014; Ogura et al. 2014; Clark et al. 2016) . More recently, the SCORE2 study assessed aflibercept dosing regimens compared to bevacizumab (Scott et al. 2017) . Patients were randomized to receive either bevacizumab or aflibercept every 4 weeks through to month 6, and then, those in the bevacizumab arm meeting a poor or marginal response at month 6 were switched to aflibercept, and those originally on aflibercept meeting a poor response were given a dexamethasone implant. SCORE2 demonstrated no difference in vision but demonstrated improved anatomical outcomes for aflibercept versus bevacizumab at 6 months (Scott et al. 2017) . Aflibercept may have superior therapeutic effect over bevacizumab and ranibizumab due to its higher binding affinity to VEGF-A and targeting a wider range of cytokines (Papadopoulos et al. 2012 ) and longer half-life (Stewart et al. 2012) . Aflibercept also inhibits both VEGF-B and PlGF, which is of importance as higher levels of intravitreal PlGF is found in eyes with retinal vascular disease (Noma et al. 2014) . As intravitreal levels of À194.00 (À243.00 to À145.00) À20.00 (À68.00 to 29.00) BCVA = best-corrected visual acuity; CMT = central macular thickness.
VEGF in CRVO are the highest measured among all retinal vascular conditions (Aiello et al. 1994; Noma et al. 2009; Shah & Shah 2011) , those with RVOs may need more effective VEGF inhibition. Due to the small number of studies, there were limited data to produce significant data by quantitatively subanalysing by RVO classification. Of the six studies investigating CRVO, only three studies included information in regard to perfusion status. One study included only patients with ischaemic CRVO, and two studies included a mixed cohort of ischaemic and nonischaemic patients. Of the two studies assessing outcomes in BRVO, only one study describes perfusion status, including patients of both perfusion states. However, it can be observed that CRVO patients responded significantly greater in terms of CMT and BCVA compared to BRVO, although this may be representative of a ceiling effect. It would be assumed that those eyes with a worse baseline BCVA and CMT would have more potential for improvement in outcomes, than those with better vision.
Of note, not all patients with RVO benefit from the use of anti-VEGF therapy, with 56.2% of those treated with anti-VEGF still having persistent macular oedema (Campochiaro et al. 2014) . Retinal nonperfusion in patients with RVOs may also contribute to restricted visual gains over the long term (Sophie et al. 2013) . The RETAIN study showed that those with ischaemia have a worse visual prognosis than those without (Sophie et al. 2013; Chatziralli et al. 2017 ). There were insufficient data assessing ischaemic patients in detail, and further research is needed in assessing the efficacy of anti-VEGF therapy in ischaemic patients.
The increased response to aflibercept in these treatment-resistant patients may be due to several factors. Firstly, the increased VEGF expression may require significantly greater VEGF blockade to achieve an effect. Secondly, the extensive number of previous injections prior to switching could also be considered a potential explanation, as the increased anatomical benefit seen after the switch could have a cumulative effect.
As only 50% of the studies considered longer term outcomes of 12 months. It is difficult to determine whether the lack of sustained benefit at 12 months, with worsening of functional but not anatomical outcomes compared to 6 months, is a reflection of reduced efficacy over time.
Of importance, these patients need to be regarded in the context that they had been extensively treated prior to the switch to aflibercept; therefore, any additional potential for visual and anatomical gains may be limited. Repeated use of any drug can result in drug resistance with a resultant loss of clinical effect (Forooghian et al. 2009; Binder 2012; Chatziralli et al. 2017) , which may be overcome by switching to an alternate therapy with a different mechanism of action. As a result, the restoration of treatment effect may be accomplished after switching, resulting in a reduction in macular oedema.
The subgroup analysis did demonstrate positive effects based on the treatment intervals, with the mean injection interval after the switch being longer than that before switching. Those studies with treatment intervals of less than 8 weeks did better to those with treatment intervals greater than 8 weeks. The COPERNICUS and GALILEO studies showed after 6 months of fixed monthly treatment 74.5% and 80% of patients were fluid free, respectively. However, after switching to a PRN regimen this had decreased to only 34.3% and 60.2% at 18 months (Heier et al. 2014; Korobelnik et al. 2014) . The longer injection interval may be due to the longer half-life of aflibercept compared with bevacizumab (Papadopoulos et al. 2012; Stewart et al. 2012) . It is difficult to establish whether the absence of prolonged benefit of aflibercept with worsening functional, but not morphological, effects is due to a reduced efficacy of anti-VEGF therapies over time or in part due to the extended treatment frequency seen in the included studies. The lack of concomitant visual gain suggests it may be related to irreversible neuroretinal degeneration and increased photoreceptor damage (Mowat et al. 2012) .
The results of this meta-analysis show a significant improvement in morphological outcomes may be achieved by switching to aflibercept in patients with persistent macular oedema at 6 months. Limitations of this meta-analysis include the following: firstly, the relatively small sample sizes, which may overestimate the treatment effect, the treatment effect in all the studies was sufficiently large to yield significant gains. Secondly, the small amount of publications available on this topic and lastly, the quality of the studies and the nonrandomized retrospective nature of the studies to sufficiently account for confounding variables. Prospective study design would offer more well-defined conclusions and limit the excessive overinterpretation of heterogeneity among retrospective studies, as seen in this review. The authors are readily anticipating the 12-month results of the SCORE2 study to aid in determining a role for switching therapy in a large prospective study.
Conclusion
This meta-analysis included all existing studies meeting inclusion criteria in assessing treatment outcomes after switching to aflibercept in eyes with persistent macular oedema secondary to RVO. There is good rationale to switch to aflibercept as the different modes of action may aide in the resolution of persistent macular oedema.
